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Role of al-proteinase inhibitor in restraining peritoneal inflammation
in CAPD patients. The concentration and functional state of a!-
proteinase inhibitor (al-PT) may modulate the expression of peritonea!
phiogosis by affecting the activity of proteases and synthesis of auta-
coids. al-PI is detectable in peritoneal effluents of peritonitis-free
patients. al-PT purified from peritoneal fluid of these patients was
biologically active both in terms of inhibition of elastase activity and of
synthesis of platelet activating factor (PAF). The biological activity of
al-PI could therefore explain the absence of detectable amounts of PAF
in peritonitis free patients despite the presence of intraperitoneal
concentrations of tumor necrosis factor-a (TNFa) that would be
sufficient per se to induce the synthesis of PAF. In patients with acute
infectious peritonitis, the concentration of immunoreactive al-PI was
significantly increased in respect to stable patients. However, al-PT
purified from patients with acute peritonitis was functionally inactive
both on proteolytic activity on elastase and on TNFa-induced PAF
synthesis by purified human PMN. The loss of al-PI activity correlated
with the number of peritoneal leukocytes and was probably dependent
on oxidative inactivation. Indeed, treatment with reducing agent re-
stored the inhibitory function of al-PT. The inactivation of al-PT in
patients with peritonitis was associated with the presence of PAF in
peritoneal dialysates. These results suggest that al-PT prevents the
proteolytic action and cell activation leading to PAF synthesis in
peritonitis free patients. However, inactivation of its function by
oxidants generated during the inflammatory process may lead to pro-
teolytic injury and unrestrained synthesis of inflammatory mediators
during peritonitis.
Concentration and functional state of aT-proteinase inhibitor
(al-PI) modulate not only the expression of inflammatory
proteases released at the site of inflammation [reviewed in TI,
but also the synthesis of autacoids such as platelet activating
factor (PAF) and leukotriene B4 (LB4) induced by tumor
necrosis factor-a (TNFa) and phagocytosis [2, 31.
al-PI can be inactivated by oxidation of two methionine
residues in the reactive site [41. Such inactivation, observed in
acute respiratory distress syndrome (ARDS) bronchoalveolar
lavage and in rheumatoid synovial fluid [5—71, may result in the
unrestrained action of the locally-released proteolytic enzymes
and in the enhancement of autacoid synthesis.
Received for publication December 9, 1991
and in revised form March 30, 1992
Accepted for publication March 30, 1992
© 1992 by the International Society of Nephrology
Since aT-PI inhibits PAF synthesis at concentrations about
TOO times lower than those present in serum, it was proposed
that the synthesis of PAF may require either inactivation or
exclusion of al-PI in zones of close contact among cells or
between cells and extracellular matrix [2].
The aim of the present paper was to study the concentration
and the functional state of al-PI in relationship with the
production of TNFa, and the local synthesis of PAF that has
been recently demonstrated in a model which provides the
unique opportunity to recover the exudate fluid, the infectious
acute peritonitis complicating CAPD [81. It was found that the
concentration of immunoreactive al-PI was significantly in-
creased in patients with acute peritonitis in respect to stable
patients. However, aT-PI recovered in patients with acute
peritonitis was functionally inactive. When submitted to reduc-
ing agents, al-PI recovered its activity, thus suggesting that
aT-PI in dialysate effluent obtained during acute peritonitis was
in a state of oxidative inactivation. The inhibition of aT-PI is
associated with the local synthesis of PAF and correlated with
the number of leukocytes in the dialysate, but not with the
intraperitoneal concentrations of TNFa that were similar in
stable and peritonitis CAPD patients.
Methods
Patients and controls
Seventeen patients (aged 60.35 4.03 years, mean sEM)
undergoing CAPD for end-stage renal failure were studied. Six
of these patients (Group A) were evaluated during episodes of
peritonitis and eleven patients (Group B), who had no present
history of peritonitis, were used as controls.
The causes of the underlying renal failure in Group A and B
patients are reported in Table T. The criteria for including the
patients in the study were: patients clinically stable and absent
of systemic diseases, such as autoimmune disease and diabetes,
and CAPD for at least two months. Peritonitis was diagnosed on
the basis of abdominal tenderness accompanied by an elevated
leukocyte count (above 300/mm3) and/or positive dialysate
culture [91.
Informed consent was obtained from all the patients included
in this study.
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Table 1. Characteristics of CAPD patients
Patient no.
Age
years Sex Primary disease Organism
Clinical
symptoms
Months
on
CAPD
Previous
episodes of
peritonitis
Group A (with peritonitis)
1 67 M Chronic glomerulonephritis Serratia Marcescens 1, 2, 3 33 2
2 71 M Nephroangiosclerosis Escherichia Coli 1, 2, 3 22 0
3 14 M Congenital hydronephrosis StaphylococcusAureus 1,2,4 31 3
4 70 M Interstitial nephropathy Pseudomonas Aeruginosci 1, 2, 3 87 2
5 58 M Nephroangiosclerosis Negative 1 4 0
6 45 F Chronic glomerulonephritis Candida Albicans 1, 2 82 3
Group B (without peritonitis)
I 66 M Nephroangiosclerosis Negative 0 32 1
2 67 M Nephroangiosclerosis Negative 0 23 0
3 70 M Interstitial nephropathy Negative 0 64 2
4 70 M Nephroangiosclerosis Negative 0 33 0
5 53 M Chronic glomerulonephritis Negative 0 19 0
6 74 F Nephroangiosclerosis Negative 0 3 0
7 31 M Chronic glomerulonephritis Negative 0 8 0
8 61 M Chronic pielonephritis Negative 0 66 1
9 79 M Nephroangiosclerosis Negative 0 43 0
10 69 M Nephroangiosclerosis Negative 0 25 0
11 61 M Interstitial nephropathy Negative 0 3 0
Dialysis technique
CAPD was performed with dialysis solutions containing
1.36% or 2.27% glucose concentration (Baxter, Sesto
Fiorentino, Italy) employing four exchanges of 1,5 to 2.0 liters
dialysate daily.
Study in patients of Group A
In Group A patients the samples of blood and of dialysate
effluent after a six-hour dwell-time were collected at the time of
the antibiotic loading dose (cephalotin I g; Keflin®, Eli Lilly &
Co, Indiana, USA; and tobramycin 1.7 mg/kg body wt, Nebic-
ma5, Eli Lilly & Co) [10]. The samples were immediately
processed for PAF extraction (5 ml of blood and 30 ml of
dialysate) and an aliquot of dialysate was filtered sterile (Mm-
isart NML 0.2 pm, Sartorius, Gottingen, Germany) and stored
at —70°C. TNFw and al-PI were determined in sera and
dialysates as described below, and an aliquot of each sample of
dialysate was fractionated by size-exclusion high pressure
liquid chromatography (HPLC).
Study in patients of Group B
For six consecutive days the extraction of PAF was per-
formed in all Group B patients in 30 ml samples of the overnight
dialysate effluents (about 10 hr dwell time). Each sample was
filtered sterile as described above, and /32-microglobulin, albu-
min, transferrin, al-PI, immunoglobulin G (IgG), cr2-macroglo-
bulin, immunoglobulin M (1gM) and TNFa were determined in
both dialysate effluents and venous blood samples in the morn-
ing.
In six patients of this Group, an aliquot of sterile frozen
dialysate was processed by HPLC as in Group A.
Chemical analysis and radioimmunoassay
A nephelometric method (Array Protein System, Beckman
Instruments, Inc., Brea, California, USA) was used to quantify
dialysate albumin, transferrin, s 1 -P1, IgG, a2-macroglobulin
and 1gM, /32-microglobulin in dialysate was determined by
radioimmunoassay (Pharmacia Diagnostics, Uppsala, Sweden)
[11].
TNFs assay
The TNFa bioactivity was measured on plasma and dialysate
samples prepared as previously described [12] and stored at 4°C
no longer than two days. After appropriate dilutions of samples
in RPMI 1640, 100 l of each dilution were added to cultures of
human SK-MEL-109 melanoma cells that are sensitive to the
cytotoxic activity of TNFa l2]. These cells were grown as
monolayers in 24-well cluster plates, incubated with appropri-
ate dilutions of serum or dialysate fluid samples, and after 18
hours washed with phosphate-buffered saline before staining
with crystal violet, which was eluted and measured as described
[12]. A calibration curve was constructed with human recom-
binant TNFs (a gift of Suntori Institute for Medical Research,
Osaka, Japan). The amounts of TNFa were expressed as U/ml,
one Unit being defined as the amount of TNFa giving 50% cell
survival. One unit corresponded to a concentration of 104 pg/mI
of human recombinant TNFa. TNFa specific cytolysis was
calculated as the cytolytic effect abrogated by preincubation of
samples with a rabbit polyclonal anti-human TNFs antibodies
(Cetus, Emerville, California, USA). Furthermore, these sam-
ples were also added to a TNFx-resistant cell line (designated
R4) selected from SK-MEL-109 cells [12]. The lack of cytotox-
icity for resistant R4 cells in such control experiments showed
that the cell death observed with sensitive SK-MEL-109 cells
was specifically caused by TNFa. The cytotoxicity assays were
carried out in triplicate and gave a standard error of <5%.
TNFa immunoreactivity was measured by an ELISA method
(T Cell Sciences, Cambridge, Massachusetts, USA) with a
sensitivity of 10 pg/mI on samples stored at —70°C.
Interleukin-1/3 assay
Interleukin- 1f3 immunoreactivity (IL-I f3) was measured with
a commercial RIA Mab method (Advanced Magnetics, Inc.
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Cambridge, Massachusetts, USA) with a detection level of 10
pg/mi on samples stored at —70°C.
Fractionation of dialysate effluents
Effluent samples were dialyzed overnight against 10 mM
phosphate buffer (pH 7.4) added with 0.15 M NaCl. The
dialyzed samples were fractionated by size exclusion HPLC
(Beckman Instruments) on a 7.5 x 600 mm column (Beckman
Spherogel TSK 2000 SW, Japan) equilibrated with the same
buffer, and eluted with this buffer through a recording spectro-
phometer at 280 nm (LKB Instruments, Inc., Gaithersburg,
Maryland, USA). The following purified proteins were used as
molecular weight markers: bovine serum albumin (68 kD),
f32-microgiobulin (11.4 kD; Sigma Chemical Co., St. Louis,
Missouri, USA) and al-PT (54 kD; Athens Research, Athens,
Georgia, USA). Eluted fractions were immediately frozen in
liquid nitrogen, stored at —70°C and lyophilized. These frac-
tions were reconstituted with distilled water before determining
the concentrations of albumin and al-PT by methods described
above.
Assay for inhibitory activity of cxl -P1
A total of 0.1 tg of al-PI of HPLC fractionated dialysates or
0.1 g of commercially available ai-PI purified from normal
human plasma (Athens Research) were incubated with 0.1 g
human neutrophil-derived elastase (Athens Research) for 30
minutes at 37°C in 200 d (final volume) of Tris-Tyrode's [KC1
2.6 mM; MgCI2 6 H20 1 mi; NaCl 137 mvt; CaCI2 6 1120 1.3
mM; Tris (hydroxymethyl amino-methane) 1 m; pH 8.0]. At
the end of incubation, 10 t1 of 6 mi chromogenic substrate
for human elastase (N-methoxysuccinyl-Ala-Ala-Pro-Val p-
nitroanilide, Sigma Chemical Co.) was added to the mixture and
vortexed [13]. Yellow color development from the hydrolysis of
the substrate was read at 410 nm using an automatized Multistat
II Plus (IL, Spokane, Washington, USA) equipped with an
in-home software program for the calculation of % variation of
each reading versus the 100% control (0.1 g of human elastase
plus chromogenic substrate).
To prove the specificity of al-PI inhibitory activity, we
preincubated the 0.1 ig al-PT containing fractionated samples
from dialysate effluents of Group B patients with different
amounts (100 50 pig, 10 g, 1 sg, 0.1 g) of a rabbit
anti-human al-PI IgG (Sigma Chemical Co.). In experiments
designed to evaluate the inhibitory activity of al-PT on the
synthesis of PAF from human PMN, ai-PI-IgG complexes were
removed by affinity chromatography on protein A Sepharose
(Sigma Co).
To clarify whether al-PT in dialysate effluents from Group A
patients may be oxidized during the inflammatory process,
reduction was performed by the method of Jon et a! [14], using
5% solution of 13-mercaptoethanol incubated with the protein
for four days at pH 8.0 at room temperature. The reduced al-PI
was exhaustively dialyzed against 0.05 M Tris HC1, 0.05 M
NaCI, pH 8.0, in a stoppered flask through which nitrogen was
bubbled to remove oxygen. As control of the reduction proce-
dure, we likewise treated oxidized al-PI prepared by the
addition of eight molar equivalents of N-chlorosuccimide to the
native protein at pH 9.0, followed by exhaustive dialysis against
0.05 M Tris HCI, 0.05 M NaCI, pH 8.0 [15].
Assay for the inhibitory activity of al-PI on the synthesis of
PAF from human PMN
Human PMN were prepared as previously described [3].
Briefly, blood from healthy donors was drawn into plastic tubes
containing 5 mM EDTA and centrifu ged for 20 minutes at 700
g. Plasma and buffy coat were removed, and pellets were
resuspended in 2 volumes of 2.5% gelatin (Difco Laboratories,
Inc., Detroit, Michigan, USA) in saline. The bulk of the
erythrocytes was removed by low speed centrifugation, and the
remaining cells were pelleted by centrifugation for 20 minutes at
700 g. The cells were subjected to osmotic shock to eliminate
contaminating erythrocytes and were washed twice with TT-
BSA without Ca and Smears of cells stained with
May-Gruenwald-Giemsa showed 85 to 95% PMN. The cells
were resuspended at 5 x 106/ml in TT-BSA with Ca + and
Mg + and preincubated with al-PT at room temperature for five
minutes. In standard assays 2.5 x 106 cells in 0.5 ml TT-BSA
with Ca and Mg + were stimulated with 20 ng/ml of TNFa
for 10 minutes at 37°C. In previous experiments [2], 20 g/ml of
purified plasma al-PI was the concentration inducing the max-
imal inhibitory activity on the synthesis of PAF from stimulated
human PMN. Cell viability, as determined by Trypan blue
exclusion test, was between 90 and 95%. PAF released into the
medium and cell associated was extracted as previously de-
scribed [3].
Purification and characterization of PAF
The effluent samples of the dialysate and plasma were ex-
tracted and purified by methods previously described for the
recovery of PAF from biological specimens [16, 17]. The
samples were acidified to pH 3.0 to 3.5 with 1 N HCI to destroy
the acid-labile inhibitor of PAF [16]. Lipids were extracted by
1.9 vol of methanol. After one hour incubation at room temper-
ature, the precipitated proteins were removed by centrifugation
and 2 volumes of chloroform, 0.1 volume of methanol and 0.8
volume water were added to the supernatant to effect phase
separation [16]. The lower chloroform-rich phase was then
subjected to thin-layer chromatography (TLC) on precoated
silica gel plates 60F254 (Merck, Darmstad, Germany), using
chloroform:methanol:water 65:35:6 vol/vol/vol [16], as the sol-
vent system. Lipid material purified on TLC was submitted to
HPLC (Beckman Instruments) equipped with a cPorasiI col-
umn (Millipore, Milford, Massachusetts, USA) developed with
chloroform:methanol:water, 60:55:5 vol/vollvol at a flow rate of
1.0 mI/mm [18]. Synthetic PAF (Bachem Feinchemikalien AG,
Switzerland), sphingomyelin and lyso-2-phosphaditylcholine
(Lyso-PC; Sigma Co.) were used as reference lipids.
The recovery of synthetic PAF, evaluated by mixing 15 ng of
synthetic PAF (1 -0-octadecyl-2-acetyl-sn-glyceryl-3-phospho-
rylcholine; Bachem Feinchemikalien AG, Bubendorf, Switzer-
land) or 0.1 cCi of [3H] PAF (120 Ci/mmol) with 30 ml of
dialysis solution. This was followed by extraction, TLC and
HPLC [17], and was 87.9 4.0% biological activity and 93.0
2.9% radioactivity.
PAF bioactive eluted from HPLC was characterized by
comparison with synthetic PAF according to the following
criteria: (1) chromatographic pattern on TLC using chloroform-
methanol-water (65:35:4 vol/vol/vol or 65:35:6 vol/vol/vol) as a
solvent, with migration between lyso-PC and sphingomyelin
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Fig. 1. Dosage of PAF (nM/liter) and immunoreactive al-PI (mg/dl) in
the dialysate of the patients ofGroup A (;N 6, with peritonitis) and
of Group B (0; N = 11, without peritonitis). Student's (-test was
performed between Group A and Group B. **> 0.02; ***> 0.001.
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[16]; (2) physicochemical characteristics such as inactivation by
strong bases, resistance to acid and weak basic conditions [16],
and inactivation by phospholipase A2 but not lipase A1 [19]; and
(3) ability to induce platelet aggregation independently from
both ADP and arachidonic acid and the thromboxane A2-
mediated pathway. The methods used have been described in
detail in previous papers [17—211.
PAF assay
After extraction and purification by TLC and HPLC, PAF
was quantified by aggregation of washed rabbit platelets in the
presence of 10 LM indomethacin (Sigma Co.), which inhibits
cyclooxygenase, and of creatine phosphate (312.5 sg/m1)/creat-
mine phosphokinase (152.5 jig/mI) enzymatic system (Sigma
Co.) which converts ADP to ATP, thus blocking the arachi-
donic acid- and ADP-dependent platelet aggregation, respec-
tively [81. The amount of PAF was calculated over a calibration
curve of synthetic PAF constructed for each test [81,
The specificity of platelet aggregation was inferred from the
inhibitory effect of platelet pretreatment (30 sec at 37°C under
continuous stirring at 900 rpm) with 3 p.M WEB 2170 (Boeh-
ringer Ingeiheim, Ingelhelm/Rh, Germany) [221 and 5 p.M CV-
3988 (Takeda Chemical Industries, Kyoto, Japan) [23], two
chemically-unrelated PAF receptor antagonists.
Statistical analysis
The following statistical tests were applied when appropriate
as indicated in the figure and table legends: Student's t-test,
one-way ANOVA with multicomparison, Newman-Keuls test,
and linear regression analysis [241. Values were given as means
SEM; P values <0.05 were considered statistically significant.
Results
Peritoneal concentrations of al-PI, TNFa and PAF
Table 1 shows the characteristics of the patients selected for
this study. In patients of Group A one out of six episodes of
peritonitis were caused by gram-positive microorganisms
(Staphylococcus aureus) , three episodes by gram-negative (Ser-
ratia Marcescens, Escherichia coli, Pseudomonas Aerugi-
nosa), one by fungi (Candida Albicans) ,and one episode was at
negative culture. Patients of Group B were peritonitis-free.
The renal residual creatinine clearance in Group A (2.31
1.47 mi/mm) was not significantly different from that of Group B
patients (2.50 0.55 mI/mm; Student's t-test P > 0.5).
The level of immunoreactive ul-PI in peritoneal effluents was
significantly increased in patients with peritonitis (Group A) in
respect to peritonitis-free patients (Group B; Fig. 1). In con-
trast, differences in the plasma and dialysate levels of TNFa
bioactivity and immunoreactivity were not statistically signifi-
cant in the two groups of patients despite higher levels of TNFa
which were detectable in patients with peritonitis (Figs. 2 and
3). The specific TNFa bioactivity that was abrogated by anti-
TNFa antibodies was higher by a factor about of 20 than TNFa
quantified by ELISA. This discrepancy may depend on syner-
gism between TNFa and other cytokines present in the sam-
ples. Indeed IL-1f was detected in the dialysate of Group B
patients (31.65 0.71 pg/ml) and in significantly higher concen-
trations in Group A (118.31 40.22 pglml; P = 0.009). In
addition TNFa bioactivity was tested within two days in
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Fig. 2. Plasma bioactive TNFa (U/mI, 1 U/mi was equivalent to
104 pg of human recombinant TNFa) and plasma immunoreactive
TNFa (pg/mi, Li) levels in 13 controls subjects (Controls), in Group A
with peritonitis (N = 6) and in Group B without peritonitis (N = 11).
ANOVA with Newman-Keuls multicomparison test was performed in
TNFa bioactive and immunoreactive levels between the following
experimental groups: Group A versus Controls (* < 0.05); Group B
versus Controls (P > 0.05); Group A versus Group B (P > 0.05).
samples stored at 4°C because freezing drastically reduced
bioactivity. The regression analysis performed between bioac-
tive TNFa and proteins with different molecular weights used
as markers for peritoneal permeability indicate that the concen-
tration of bioactive TNFa does not correlate with any of these
protein markers (Table 2). This occurred despite the highly
significant correlation between dialysate albumin and all the
other protein markers (Table 2). As previously described [8]
and with a difference in the data regarding TNFa, the biologi-
cally active PAF was detected only in peritoneal dialysate of
CAPD patients with peritonitis (Group A; Fig. 1). In all patients
no PAF was detected in plasma, suggesting that during perito-
nitis PAF is synthesized locally.
Mariano et a!: oil -proteinase inhibitor in inflammation 739
Mean±sEM
Versus
r
TNFa
P
Versus
r
albumin
P
TNFa U/mI 12.38 2.6 — — — —
/32-microglobulin 7.28 0.38 —0.220 0.8780 0.4615 <0.001
isgiliter
ni-PI mg/dl 5.67 0.38 —0.0911 0.5249 0.7123 <0.001
Albumin mgldl 98.25 3.76 —0.0871 0.5435 — —
Transferrin mgldl 6.75 0.37 0.1126 0.4313 0.7621 <0.001
Immunoglobulin G 22.35 1.57 0.0203 0.8876 0.8953 <0.001
mg/di
a2-macroglobulin 1.68 0.16 0.0047 0.9741 0.7388 <0.001
mgldl
Immunoglobulin M 0.95 0.11 0.0565 0.6937 0.7283 <0.001
mg/di
Functional studies of peritoneal al-PI
The functional studies on peritoneal al-PI were performed
after fractionation of dialysate effluents by size exclusion HPLC
(Fig. 4). The eluted fractions were tested for the presence of
immunoreactive al-PI. The latter was eluted with a retention
time of 12 minutes, which was similar to that of purified plasma
al-PI. The percent of recovery was 75.2 5.9. The assay for
inhibitory activity of csl-PI on elastase indicated that, despite
the significantly increased concentrations of immunoreactive
al-PI in peritonitis, the latter was functionally inactive (Fig. 5).
In contrast, the al-PI detected in peritonitis-free patients
(Group B) retained an inhibitory activity on elastase compara-
ble to that of purified plasma al-PI. Preabsorption of peritoneal
al-PI-containing fractions of Group B (peritonitis free) with 50
g rabbit anti-human al-PI IgG completely abrogated the
inhibitory activity on elastase (Fig. 5).
Peritoneal a 1-PI-containing fractions from peritonitis-free
patients (Group B) inhibited the synthesis and release of PAF
from normal human PMN stimulated with TNFs (Table 3) and
with IL-1f3 (data not shown), similar to what was observed with
purified plasma al-PI. This inhibitory activity was abrogated by
preabsorption with the anti-al-PI IgG and by oxidation (Table
3). In contrast, the inhibitory activity of peritoneal al-PI-
containing fractions from peritonitis patients (Group A) on PAF
synthesis was significantly reduced. Treatment of fractions
containing inactive al-PI from peritonitis patients (Group A) as
well as of oxidized purified plasma al-PI with /3-mercaptoeth-
anol, a reducing agent, restored the inhibitory function both on
the activity of elastase (Fig. 5) and on the synthesis of PAF
(Table 3). The inactivation of al-PI purified from dialysates was
directly correlated with the number of peritoneal leukocytes
(Fig. 6).
The inactivation of al-PI was reversed in three patients with
peritonitis (Group A) that were studied three months after the
recovery (97.97 0.44 of inhibitory activity on elastase).
Discussion
The presence and functional integrity of al-PI has received
increasing attention as it may restrain proteolytic attack of
neutrophil elastase on tissue structures in various inflammatory
conditions [25]. Several studies indicate that in inflammatory
diseases, a correlation exists between the release of neutrophil
elastase, a marker of lysosomal enzymes, and the clinical
situation of patients [5—7].
The main inhibitor of neutrophil elastase is the al-PI [26]. It
was found that the severe genetic deficiency of this protein
commonly results in pulmonary emphysema [27]. The observa-
tion that emphysema also occurs in most smokers despite
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Fig. 3. Dialysate bioactive TNFa (U/in!, ) and dialysate immunore-
active TNFa (pg/mi, E) levels in Group A with peritonitis (N = 6) and
in Group B without peritonitis (N = 11). Student's t-test between Group
A and Group B bioactive TNFa or immunoreactive TNFa is not
statistically significant (P > 0.05).
Table 2. Regression analysis between TNFa or albumin versus
proteins of differents molecular weight (Group B peritonitis free,
N = 11 patients, N = 66 exchanges)
0
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Fig. 4. Representative chromatographic pattern of peritoneal dialy-
sate from a patient of Group B submitted to size exclusion HPLC
(Beckman Apparatus) on 7.5 X 600 mm column (Spherogel TSK 2000
SW) (data in Methods). The biological activity and immunoreactive
al-PI was eluted with a retention time of 12 mm.
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Fig, 6. Regression analysis between the number of leukocytes in the
dialysate and inhibitory activity of al-PI present in the dialysate of
Group A (with peritonitis) and of Group B (without peritonitis); P <
0.002.
dialysate with (Group A) and without (Group B) peritonitis on TNFa-
induced PAF synthesis by purified human PMN
Platelet activating factor ng
Additions g/ml Cell associated Released
None — 0.5 0.2 0.0
TNFa — 6.5 0.2 3.9 0.7
TNFa + plasma aI-PI 20 3.1 o.2 00°
TNFa + oxidized plasma 20 6.6 0,5b 4.1 0.6"
al-Pt
TNFa + reduced plasma 20 3.2 0.3 0.9 0.3
al-PI
TNFa + Group B 20 3.3 0.5 0.8 0.4°
peritoneal al-Pt
TNFa + Group B 20 6.8 0.6° 4.2 0.5°
peritoneal al-PI + anti-
al-PI IgG
TNFa + Group A 20 6.7 0,4b,c 3.6 0.5"°
peritoneal aI-PI
TNFa + Group A reduced 20 3.9 0.6 1.1 0.6
peritoneal al-Pt
For each assay, 2.5 x 106 human PMN were preincubated for 5
minutes with al-Pt purified from human plasma and from dialysates of
patients with (Group A) and without (Group B) peritonitis and stimu-
lated with TNFa 20 ng/ml for 10 minutes at 37°C. Plasma al-Pt was
oxidized and then reduced according to Jon et a!. (14]. Group B
peritoneal al-Pt was treated with 50 sg of anti-al-Pt IgG/0. I jg al-Pt
and immune complexes were removed by affinity chromatography with
protein A Sepharose. Group A peritoneal al-PI was exposed to
reducing conditions as described in [14], The cell associated and
released PAF were measured as described in Methods. ANOVA with
Newman-Keuls multicomparison test was performed in cell associated
and in released PAF amounts between the following experimental
groups:
a TNFa versus TNFa + plasma al-Pt, TNFa + Group B peritoneal
al-PI and TNAa + Group A peritoneal al-Pt (P < 0.05 vs. TNFa)b TNFa + plasma al-Pt versus TNFa + oxidized plasma al-Pt,
TNFa + reduced plasma al-PI, TNFa + Group B peritoneal al-Pt,
TNFa + Group A peritoneal al-Pt, TNFa + Group A reduced
penitoneal al-PI (P < 0.05 vs. TNFa + plasma aI-PI)
TNFa + Group B peritoneal al-Pt versus TNFa + Group B
peritoneal al-Pt + anti-al-PI IgG, TNFa + Group A peritoneal al-Pt
and TNFa + Group A reduced peritoneal al-Pt (P < 0.05 vs. TNFa +
Group B peritoneal al -P1)
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Fig. 5. Assay for inhibitory activity (on
human !eukocyte elastase 0.1 sg) of' al-PI
0.1 tg from the dialysate of Group A (with
peritonitis); Group B (without peritonitis);
Group A after reduction with 13-
mercaptoethanol; Group B after pretreatment
with rabbit anti-al -P1 JgG and of pu,ified
commercial al-Pt (Methods). ANOVA with
Newman-Keuls multicomparison test was
performed among the following groups: Group
A versus Group B, Group A after reduction
and purified al-Pt (* < 0.05 vs. Group A);
Group B versus Group A after reduction,
Group B after Ab pretreatment and purified
aI-PI (#P < 0.05 versus Group B); Group A
after reduction versus purified al-PI (P >
0.05).
y = 120.25 + 33.92x
r= 0.8131
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normal levels of immunoreactive al-Piled to the discovery that
the oxidation of al-PI due to inhalation of oxidants present in
tobacco smoke and ozone [281 may produce loss of the al-PI
inhibitory function.
In addition, oxidants released from cells during inflammatory
reaction may be responsible for inactivation of al-PI. Func-
tional inactivation of this protein was indeed observed in
inflammatory diseases such as ARDS [5, 6] and rheumatoid
arthritis [7].
Proteases are deeply implicated in the development of inflam-
matory injury due to their ability to trigger synthesis and release
of mediators from cells, in addition to their action on extracellular
matrix [1, 29]. In this regard, al-PI plays a central role in
modulating cell activation. It was indeed found in in vitro exper-
iments that al-PI inhibited the synthesis and release of auta-
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